0001209191-22-062643.txt : 20221223
0001209191-22-062643.hdr.sgml : 20221223
20221223170307
ACCESSION NUMBER: 0001209191-22-062643
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221101
FILED AS OF DATE: 20221223
DATE AS OF CHANGE: 20221223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 221486001
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-01
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2022-11-01
4
P
0
65
2.53
A
54506
D
Common Stock
2022-11-02
4
P
0
65
2.54
A
54571
D
Common Stock
2022-11-03
4
P
0
65
2.44
A
54636
D
Common Stock
2022-11-04
4
P
0
65
2.42
A
54701
D
Common Stock
2022-11-07
4
P
0
65
2.45
A
54766
D
Common Stock
2022-11-08
4
P
0
65
2.42
A
54831
D
Common Stock
2022-11-09
4
P
0
65
2.37
A
54896
D
Common Stock
2022-11-10
4
P
0
65
2.37
A
54961
D
Common Stock
2022-11-11
4
P
0
65
2.32
A
55026
D
Common Stock
2022-11-14
4
P
0
65
2.32
A
55091
D
Common Stock
2022-11-15
4
P
0
65
2.35
A
55156
D
Common Stock
2022-11-16
4
P
0
65
2.31
A
55221
D
Common Stock
2022-11-17
4
P
0
65
2.29
A
55286
D
Common Stock
2022-11-18
4
P
0
65
2.27
A
55351
D
Common Stock
2022-11-21
4
P
0
65
2.38
A
55416
D
Common Stock
2022-11-22
4
P
0
65
2.37
A
55481
D
Common Stock
2022-11-23
4
P
0
65
2.29
A
55546
D
Common Stock
2022-11-25
4
P
0
65
2.31
A
55611
D
Common Stock
2022-11-28
4
P
0
65
2.37
A
55676
D
Common Stock
2022-11-29
4
P
0
65
2.34
A
55741
D
Common Stock
2022-11-30
4
P
0
65
2.32
A
55806
D
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.
Joseph C. Galante by /s/ John Hamm as
attorney-in-fact
2022-12-23